Inhibikase Therapeutics Inc • IKT

Capital at risk.

About Inhibikase Therapeutics Inc
Ticker
info
IKT
Trading on
info
NASDAQ
ISIN
info
US45719W2052
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Mark T. Iwicki
Headquarters
info
3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339
Employees
info
15
Website
info
inhibikase.com
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Metrics
BasicAdvanced
Market cap
info
$138M
P/E ratio
info
-
EPS
info
-$0.58
Dividend Yield
info
0.00%
Beta
info
0.95
Forward P/E ratio
info
0
EBIDTA
info
$-39.5M
Ex dividend date
info
-
Price & volume
Market cap
info
$138M
Average daily volume
info
0.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
1,000,000
Price to book
info
1.6
Earnings
EPS
info
-$0.58
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-39.5M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.95
52-week High
info
$4.20
52-week Low
info
$1.12
50-day moving average
info
$1.94
200-day moving average
info
$2.27
Short ratio
info
13.86
Short %
info
5.28%
Management effectiveness
ROE (TTM)
info
-79.02%
ROA (TTM)
info
-46.95%
Profit margin
info
0.00%
Gross profit margin
info
$-25M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-100.00%
Share stats
Outstanding Shares
info
74.3M
Float
info
24.9M
Insiders %
info
13.02%
Institutions %
info
74.22%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 2 analysts.

Average price target

info
$8.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.66
-$0.67
1.49%
Q2 • 24Beat
-$0.65
-$0.37
-75.68%
Q3 • 24Missed
-$0.17
-$0.09
-101.73%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-12.1M
-46,177.12%
Q4 • 24
$0M
$-13.7M
-∞%
Q1 • 25
-100.00%
12.74%
∞%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$98.6M
$3.7M
3.79%
Q4 • 24
$94.3M
$8.6M
9.07%
Q1 • 25
-4.38%
129.02%
139.51%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-5.3M
$-38.8M
$99.7M
$-5.3M
Q4 • 24
$-4.1M
$21.1M
$0M
$-4.1M
Q1 • 25
-23.24%
-154.32%
-100.00%
-23.24%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Inhibikase Therapeutics Inc share?
Collapse

Inhibikase Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Inhibikase Therapeutics Inc have?
Collapse

Inhibikase Therapeutics Inc currently has 74.3M shares.

Does Inhibikase Therapeutics Inc pay dividends?
Collapse

No, Inhibikase Therapeutics Inc doesn't pay dividends.

What is Inhibikase Therapeutics Inc 52 week high?
Collapse

Inhibikase Therapeutics Inc 52 week high is $4.20.

What is Inhibikase Therapeutics Inc 52 week low?
Collapse

Inhibikase Therapeutics Inc 52 week low is $1.12.

What is the 200-day moving average of Inhibikase Therapeutics Inc?
Collapse

Inhibikase Therapeutics Inc 200-day moving average is $2.27.

Who is Inhibikase Therapeutics Inc CEO?
Collapse

The CEO of Inhibikase Therapeutics Inc is Mark T. Iwicki.

How many employees Inhibikase Therapeutics Inc has?
Collapse

Inhibikase Therapeutics Inc has 15 employees.

What is the market cap of Inhibikase Therapeutics Inc?
Collapse

The market cap of Inhibikase Therapeutics Inc is $138M.

What is the P/E of Inhibikase Therapeutics Inc?
Collapse

The current P/E of Inhibikase Therapeutics Inc is null.

What is the EPS of Inhibikase Therapeutics Inc?
Collapse

The EPS of Inhibikase Therapeutics Inc is -$0.58.

What is the PEG Ratio of Inhibikase Therapeutics Inc?
Collapse

The PEG Ratio of Inhibikase Therapeutics Inc is null.

What do analysts say about Inhibikase Therapeutics Inc?
Collapse

According to the analysts Inhibikase Therapeutics Inc is considered a buy.